Deal H, Steele J K, Stammers A T, Singhai R, Levy J G
Department of Microbiology, University of British Columbia, Vancouver, Canada.
Cancer Immunol Immunother. 1989;28(3):193-8. doi: 10.1007/BF00204988.
Previously we have described the isolation and characterization of a T-suppressor factor (TsF) from a T cell hybridoma (A10F), which has a degree of specificity for the DBA/2 mastocytoma P815. Administration of A10F intravenously at the time of tumor cell injection resulted in an accelerated rate of tumor growth, decreased cytotoxic T lymphocyte antitumor activity, and reduced survival time. In the work reported here, we have shown that administration of affinity-enriched A10F 7-14 days prior to tumor cell injection causes what appear to be reverse effects, in that an enhanced resistance to the P815 tumor is observed in vivo, an effect which we can correlate with the demonstration of antitumor cytotoxic T lymphocyte activity in vitro. These effects are dose-dependent since only doses of TsF at 20 micrograms or greater are effective. A similar effect was found when A10F was administered to DBA/2 mice 10 days prior to challenge with two unrelated tumors (L1210 and M-1). However, when another TsF (Fd11F) with apparent specificity for a nominal antigen was tested in this system, it had no effect on tumor growth.
此前我们已经描述了从T细胞杂交瘤（A10F）中分离和鉴定出一种T抑制因子（TsF），它对DBA/2肥大细胞瘤P815具有一定程度的特异性。在肿瘤细胞注射时静脉注射A10F会导致肿瘤生长速度加快、细胞毒性T淋巴细胞抗肿瘤活性降低以及存活时间缩短。在本文报道的研究中，我们发现，在肿瘤细胞注射前7 - 14天给予亲和富集的A10F会产生似乎相反的效果，即体内观察到对P815肿瘤的抵抗力增强，我们可以将这种效果与体外抗肿瘤细胞毒性T淋巴细胞活性的表现联系起来。这些效果是剂量依赖性的，因为只有20微克或更高剂量的TsF才有效。当在挑战两种无关肿瘤（L1210和M - 1）前10天将A10F给予DBA/2小鼠时，也发现了类似的效果。然而，当在该系统中测试另一种对名义抗原具有明显特异性的TsF（Fd11F）时，它对肿瘤生长没有影响。
